Skip to main content
SpringerLink
Log in

Prostate Cancer: Locoregional Disease

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3343 Accesses

Abstract

Prostate cancer (PCa) is the most frequently diagnosed solid tumor among men and the third leading cause of cancer-related deaths. This is a multifactorial disease, in which constitutional and environmental risk factors play an essential role in the carcinogenesis process. The screening program for PCa consists in a periodic prostate-specific antigen (PSA) blood test and digital rectal exam (DRE). Therefore, there is a significant risk of over-diagnosis and over-treatments as demonstrated by several clinical trials. Approximately 80% of newly diagnosed PCa is represented by localized disease. Surgery and radiant therapy represent accepted alternatives for the treatment of localized PCa. Randomized trials directly comparing these two approaches still lack. Moreover, for men with low-risk PCa and life expectancy of 10 years or less, active surveillance and watchful-waiting are two observational approaches that have been introduced to delay or avoid curative treatment without compromising long-term cancer-specific survival in a selected population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. SEER Cancer Statistics Review (1975–2014). National Cancer Institute, Bethesda, November 2016. http://seer.cancer.gov/csr/1975_2014/. Posted to the SEER web site April 2017.

  2. Montie JE. Observations on the epidemiology and natural history of prostate cancer. Urology. 1994;44:2–8.

    Article  Google Scholar 

  3. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30(2):143–8.

    Article  PubMed  Google Scholar 

  4. Kheirandish P. Ethnic differences in prostate cancer. Br J Cancer. 2011;105(4):481–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Leitzmann MF. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Laurence N. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. 1999;91:414–28.

    Article  Google Scholar 

  7. Wolters T. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126:2387.

    CAS  PubMed  Google Scholar 

  8. Shoag JE, Reevaluating PSA. Testing rates in the PLCO trial. N Engl J Med. 2016;374:1795.

    Article  PubMed  Google Scholar 

  9. Ilic D. Screening for prostate cancer: an updated cochrane systematic review. BJU Int. 2011;107:882.

    Article  PubMed  Google Scholar 

  10. Mottet N. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

    Article  PubMed  Google Scholar 

  11. Wolf AM. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98.

    Article  PubMed  Google Scholar 

  12. Tchetgen MB. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am. 1997;24:283.

    Article  CAS  PubMed  Google Scholar 

  13. Punglia RS. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335.

    Article  PubMed  Google Scholar 

  14. Catalona WJ. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283.

    Article  PubMed  Google Scholar 

  15. Ahmed HU. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815.

    Article  PubMed  Google Scholar 

  16. Panebianco V. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol. 2015;33:17e1.

    Article  Google Scholar 

  17. Somford DM. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190:1728.

    Article  CAS  PubMed  Google Scholar 

  18. Gordon LG. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. J Magn Reson Imaging. 2017;45:1304.

    Article  PubMed  Google Scholar 

  19. Eichler K. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–12.

    Article  PubMed  Google Scholar 

  20. Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012;60:59–74.

    Article  PubMed  Google Scholar 

  21. Gleason DF. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.

    Article  CAS  PubMed  Google Scholar 

  22. Epstein JI. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.

    Article  PubMed  Google Scholar 

  23. Pierorazio PM. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–60.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Epstein JI. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428–35.

    Article  PubMed  Google Scholar 

  25. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.

    Article  PubMed  Google Scholar 

  26. Hoivels AM. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–95.

    Article  Google Scholar 

  27. Briganti A. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57:551–8.

    Article  PubMed  Google Scholar 

  28. Prostate Cancer Clinical Guideline Update Panel. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. American Urological Association, 2017. Available at: https://www.auanet.org/guidelines/clinically-localized-proste-cancer-new-(aua/astro/suo-guideline-2017). Accessed 22 July 2017.

  29. Hamdy FC. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–24.

    Article  PubMed  Google Scholar 

  30. Bill-Axelson A. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wilt TJ. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bianco FJ. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology. 2005;66:83.

    Article  PubMed  Google Scholar 

  33. Yaxley JW. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388:1057.

    Article  PubMed  Google Scholar 

  34. Allan C. Laparoscopic versus robotic-assisted radical prostatectomy for the treatment of localised prostate cancer: a systematic review. Urol Int. 2016;96:373.

    Article  PubMed  Google Scholar 

  35. Messing EM, Eastern Cooperative Oncology Group Study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–9.

    Article  CAS  PubMed  Google Scholar 

  36. De Carlo F. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review. Urol Int. 2014;93:373–83.

    Article  PubMed  Google Scholar 

  37. Ficarra V. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):405–17.

    Article  PubMed  Google Scholar 

  38. Brame RS. Regarding the focal treatment of PCa: inference of the Gleason grade from MRI. Int J Radiat Oncol Biol Phys. 2009;74(1):110–4.

    Article  PubMed  Google Scholar 

  39. Bagshaw MA. Radiation therapy for localized prostate cancer. Justification by long-term follow-up. Urol Clin North Am. 1990;17(4):787–802.

    Article  CAS  PubMed  Google Scholar 

  40. Perez CA. Clinical assessment of outcome of prostate cancer (TCP, NTCP). Rays. 2005;30(2):109–20.

    PubMed  Google Scholar 

  41. Pollack A. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18(23):3904–11.

    Article  CAS  PubMed  Google Scholar 

  42. Zietman AL. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–9.

    Article  CAS  PubMed  Google Scholar 

  43. Roach M. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904–11.

    Article  PubMed  Google Scholar 

  44. Zelefsky MJ. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71(4):1028.

    Article  PubMed  Google Scholar 

  45. Zelefsky MJ. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241.

    Article  CAS  PubMed  Google Scholar 

  46. Zelefsky MJ. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125.

    Article  PubMed  Google Scholar 

  47. Pinkawa M. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol. 2008;184(12):679–85.

    Article  PubMed  Google Scholar 

  48. Noel C. Prediction of intrafraction prostate motion: accuracy of pre- and post-treatment imaging and intermittent imaging. Int J Radiat Oncol Biol Phys. 2009;73(3):692–8.

    Article  PubMed  Google Scholar 

  49. Slater JD. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59(2):348–52.

    Article  PubMed  Google Scholar 

  50. Gardner BG. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167(1):123–6.

    Article  CAS  PubMed  Google Scholar 

  51. Nag S. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789.

    Article  CAS  PubMed  Google Scholar 

  52. Davis BJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6.

    Article  PubMed  Google Scholar 

  53. Wojcieszek P. Prostate cancer brachytherapy: guidelines overview. J Contemp Brachytherapy. 2012;4(2):116.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Davis BJ. ACR appropriateness criteria: permanent source brachytherapy for prostate cancer. Brachytherapy. 2017;16:266.

    Article  PubMed  Google Scholar 

  55. Sanda MG. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008;358:1250.

    Article  CAS  PubMed  Google Scholar 

  56. Sheets NC. Intensity modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hamdy FC. 10-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1415.

    Article  PubMed  Google Scholar 

  58. Donovan JL. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Stone NN. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009;73:341.

    Article  PubMed  Google Scholar 

  60. Koonz BF. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate and high-risk prostate cancer. Brachytherapy. 2009;8:191.

    Article  Google Scholar 

  61. Morris WJ. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated esternal beam boost for high and intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:275.

    Article  PubMed  Google Scholar 

  62. Hsu IC. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78:751.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Hoskin PJ. Randomized trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localized prostate cancer. Radiother Oncol. 2012;103:217.

    Article  PubMed  Google Scholar 

  64. Denham JW. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9.

    Article  CAS  PubMed  Google Scholar 

  65. Roach M. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.

    Article  PubMed  Google Scholar 

  66. Bolla M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–6.

    Article  CAS  PubMed  Google Scholar 

  67. Hanks GE. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–8.

    Article  CAS  PubMed  Google Scholar 

  68. Bolla M. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    Roberto Iacovelli

  2. University of Verona, Medical Oncology Unit, Verona, Italy

    Chiara Ciccarese

  3. Medical Oncology Unit, “Sapienza” University of Rome, Rome, Italy

    Claudia Mosillo

  4. Radiotherapy Unit, University of Verona, Verona, Italy

    Renzo Mazzarotto

  5. Urology Unit, University of Verona, Verona, Italy

    Maria Angela Cerruto

Authors
  1. Roberto Iacovelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Mosillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Ciccarese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Renzo Mazzarotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Angela Cerruto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Iacovelli, R., Mosillo, C., Ciccarese, C., Mazzarotto, R., Cerruto, M.A. (2021). Prostate Cancer: Locoregional Disease. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_47

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation